ALBUQUERQUE, New Mexico, November 9, 2011 /PRNewswire/ --
A new diagnostic kit which takes the uncertainty out of lymphoma diagnosis, has been launched at the Veterinary Cancer Society's annual conference this month.
Developed by PetScreen (http://www.pet-screen.com) in the UK, the announcement is a significant breakthrough in the diagnosis of canine lymphoma with the major benefit being that it is able to differentiate between patients with lymphadenopathy due to lymphoma and lymphadenopathy due to other ailments such as lymphoid hyperplasia.
The announcement also signals a partnership and commercial venture between PetScreen Ltd and Tridelta Development Ltd to jointly develop manufacture and market a unique range of veterinary cancer diagnostic kits under the banner of 'Tri-Screen' (http://www.tri-screen.net). PetScreen has established the first reference laboratory offering the Advanced Lymphoma Blood Test (ALBT) utilising the Tri-Screen Canine Lymphoma assay kit. The kit is available now to enable laboratories worldwide to offer veterinarians this advanced testing system.
For the past two years, PetScreen's research team have been busy characterising and identifying the biomarkers used in their earlier lymphoma blood test. They found that two of the markers are Acute Phase Proteins (APP's). Although APP's have been investigated in veterinary medicine for some time PetScreen has developed a unique multi-marker approach which led to the development of patented and copyrighted analytical algorithms which combine the relative values of both Haptoglobin and C-Reactive Protein (CRP) in serum.
By enlisting the support of vets in the UK and USA the assay has been rigorously tested with 194 canine patients with lymphoma, benign lymphoid hyperplasia and other diseases with similar presentation to lymphoma as well as healthy
Copyright©2010 PR Newswire.
All rights reserved